Celltrion sets up Chinese JV and eyes manufacturing facility in country

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Rawpixel)
(Image: Getty/Rawpixel)

Related tags: Celltrion, Nan Fung Group, Vcell Healthcare, China

Celltrion has partnered with Nan Fung Group to create Vcell Healthcare, which will manufacture and commercialize three of Celltrion’s biosimilar products in China.

As part of the joint venture, Celltrion will provide Vcell with exclusive rights in mainland China to its three US and European Union (EU) approved biosimilars: CT-P13 (Remsima), CT-P10 (Truxima), and CT-P6 (Herzuma).

The three biosimilars are Celltrion’s versions of Remicade (infliximab), MabThera (rituximab), and Herceptin (trastuzumab), respectively.

According to a statement, the newly established biopharma company will seek regulatory approval in China and will look to launch ‘expeditiously’. Whilst this process is ongoing, the partnership will look to establish a ‘world-class biologics manufacturing facility’ in China.

As well as providing the manufacture for Vcell’s portfolio of biosimilars, it was also suggested that the facility could be used to provide contract development and manufacturing organization (CDMO) capabilities.

Antony Leung, CEO of Nan Fung Group, said, “China has huge unmet medical needs for high quality drugs with affordable prices. We hope Vcell Healthcare could bring world-class biosimilar products to benefit Chinese patients and establish a state-of-the-art manufacturing base in China to serve the growing demand for high quality CDMO [services] in the country.”

Celltrion’s chairman, Seo Jung-Jin, suggested that the joint venture will serve as the ‘cornerstone’ for the company’s entry into the Chinese market.

The move is part of a wider plan the company has to rapidly expand​ its business moving towards 2030, which sees the South Korean company aiming to develop one million liters of capacity for the production of biologics across its global production sites.

Related news

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us

Products

View more

Webinars